Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, 31096 Haifa, Israel.
J Neuroimmunol. 2012 Oct 15;251(1-2):45-54. doi: 10.1016/j.jneuroim.2012.07.003. Epub 2012 Jul 28.
Laquinimod is an orally administered drug under development for the treatment of Multiple Sclerosis (MS), lacking a fully elucidated mode of action. We assessed the immunomodulatory effects of laquinimod in vitro on human B cells from healthy or MS patients, cultured alone or with CD4(+) T cells. Laquinimod modulated B cell markers, mainly by increasing the regulatory ones CD25, IL10 and CD86, and decreased IL4, while increasing IL10 and TGFβ in both B and T cells, in a B cell-mediated manner. These findings shed additional light on the mechanisms underlying the effects of laquinimod in MS and potentially other immune-mediated diseases.
拉喹莫德是一种正在开发的用于治疗多发性硬化症（MS）的口服药物，其作用机制尚未完全阐明。我们评估了拉喹莫德在体外对来自健康或 MS 患者的人 B 细胞的免疫调节作用，这些 B 细胞单独培养或与 CD4(+)T 细胞共培养。拉喹莫德调节 B 细胞标志物，主要通过增加调节性标志物 CD25、IL10 和 CD86，并减少 IL4，同时增加 B 和 T 细胞中的 IL10 和 TGFβ，以 B 细胞介导的方式。这些发现进一步阐明了拉喹莫德在 MS 及潜在其他免疫介导性疾病中的作用机制。
